Available at: Continue reading Findings: 84.1% of users reported no hair loss 1.2% of users with no prior history of hair loss reported new hair loss Over 90% of the users with pre-existing hair loss (approximately 13%) experienced worsening of their hair loss Lets look at these numbers in more detail
In aggregate, lowering insulin and IGF-1, tilting the leptinadiponectin balance, elevating -hydroxybutyrate production, tempering inflammatory cytokines, restricting specific amino acids such as methionine or serine, and timing nutrient intake collectively impose a systemic head-wind that slows tumor growth and invigorates immune surveillance
Moreover, rGO is less cytotoxic than GO even at higher concentrations [94, 95]
Accessed 7/1/19
Clinician-guided care with semaglutide or tirzepatide, built around you
Together, we built on our shared scientific foundations to further advance this work and secure larger funding to support the translational progression of the project
